Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

CDMO Avid Bioservices, Inc.

退市 09-04 09:53:58 EDT

12.49

+0.00

0.00%

最高12.49	最低12.49	成交量0.00
今开12.49	昨收12.49	日振幅0.00%
总市值7.99亿	流通市值6.32亿	总股本6,396万
成交额0.00	换手率0.00%	流通股本5,062万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"CDMO","market":"US","secType":"STK","nameCN":"Avid Bioservices, Inc.","latestPrice":12.49,"timestamp":1788530038793,"preClose":12.49,"halted":4,"volume":0,"delay":0,"changeRate":0,"floatShares":50623090,"shares":63963302,"eps":-2.394638,"marketStatus":"退市","change":0,"latestTime":"09-04 09:53:58 EDT","open":12.49,"high":12.49,"low":12.49,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.394638,"tradingStatus":0,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1788552000000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":12.49,"volumeRatio":0},"requestUrl":"/m/hq/s/CDMO","defaultTab":"news","newsList":[{"id":"2664587386","title":"药石科技：拟投建南京CDMO创新基地 总投资约20亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664587386?lang=zh_cn&edition=full","pubTime":"2026-09-03 17:37","pubTimestamp":1788428254,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["CDMO","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662713592","title":"上海：到2030年，战略性新兴产业增加值达2.1万亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662713592","media":"澎湃新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662713592?lang=zh_cn&edition=full","pubTime":"2026-08-26 19:05","pubTimestamp":1787742300,"startTime":"0","endTime":"0","summary":"据上海市人民政府官网2026年8月26日消息，《上海市战略性新兴产业发展“十五五”规划》近日发布。到2030年，战略性新兴产业增加值达2.1万亿元，工业战略性新兴产业总产值占规模以上工业总产值比重达50%以上，三大先导产业制造业年均增速达10%以上。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2026-08-26/doc-iniprytn5569476.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-08-26/doc-iniprytn5569476.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["ARTY","BK6511","AGIX","BK6092","VTHR","AIPO","5RE.SI","LNGR","CDMO","QTOC","BK4139","CHAT","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661567229","title":"美银证券：CDMO业务上行周期带动康龙化成(03759)增长 目标价升至38.4港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2661567229","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661567229?lang=zh_cn&edition=full","pubTime":"2026-08-24 15:27","pubTimestamp":1787556446,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，美银证券发布研报称，将康龙化成(03759)目标价由32.3港元上调至38.4港元，维持\"买入\"评级。康龙化成2026年上半年收入年度同比增长17.9%至76亿元人民币，各业务均录得增长，其中实验室服务收入年度同比增长13.7%，CDMO收入年度同比增长32.8%，临床开发收入年度同比增长13.8%，CDMO毛利率提升2.7个百分点，但被实验室及临床服务受压所部分抵消。考虑到CDMO、实验室服务及临床开发业务快速增长，以及全球口服GLP-1业务的能见度，美银证券将康龙化成2026至2028年收入预测分别上调4%、8%及12%，看好该公司CDMO业务上行周期可带来增长。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1484124.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300759","CDMO","161027","EWH","03759"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661606422","title":"东曜药业-B(01875)发布中期业绩 总收入2.46亿元 CDMO业务高速增长 自研产品加速出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2661606422","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661606422?lang=zh_cn&edition=full","pubTime":"2026-08-21 19:55","pubTimestamp":1787313304,"startTime":"0","endTime":"0","summary":"智通财经APP讯，东曜药业-B 发布截至2026年6月30日止六个月中期业绩，2026年上半年，公司合约开发和制造组织项目管线及在手订单快速增长。CMC项目总数由2025年6月30日的98个增至2026年6月30日的134个。2026年上半年，公司总收入为人民币2.46亿元。该下降主要由于自研产品销售收入减少所致，而CDMO业务毛利随该板块业务增长相应提升。2026年上半年，公司持续高效履约，稳步保障全球客户订单交付，CDMO业务实现大幅增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1483573.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01875","BK1161","BK4139","CDMO","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658598104","title":"医药投资向制造端扩散，原料药、CDMO等现配置窗口","url":"https://stock-news.laohu8.com/highlight/detail?id=2658598104","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658598104?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:06","pubTimestamp":1786352768,"startTime":"0","endTime":"0","summary":"以多肽、ADC、小核酸等为代表的新型分子药物正处于高速迭代期，这为医药制造业提供了持续的结构性增量来源，使其区别于需求饱和后总量萎缩的传统制造业。　　近日，全球医药研发生产外包龙头药企披露其2026年半年度业绩，上半年实现归母扣非净利润105.72亿元，同比增长89.39%。展望未来，医药制造与创新药有望形成双引擎，共同引领医药板块逐步走向复苏。　　医药制造的涵盖范围很广，CDMO、原料药和医疗器械是我们比较看好的三个方向。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/10/20260810555644.jpeg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/10/20260810555644.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/shichangjuejin/20260810/32330541.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["159938","09939","BK1515","BK4139","BK1574","BK1161","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657753693","title":"港股异动 | 创胜集团医药-B(06628)午前涨超11% 拟1.9亿元出售CDMO资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2657753693","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657753693?lang=zh_cn&edition=full","pubTime":"2026-08-07 11:27","pubTimestamp":1786073234,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创胜集团医药-B午前涨超11%，截至发稿，涨11.22%，报1.14港元，成交额34.07万港元。消息面上，创胜集团医药-B发布公告，于2026年8月6日，卖方与买方杭州明德生物医药技术有限公司订立资产购买协议，卖方有条件同意出售，而买方有条件同意购买 CDMO资产，总代价为人民币1.9亿元。于二期完成后，本公司将不再于CDMO资产中拥有任何权益。CDMO资产主要包括本集团过往提供CDMO服务所涉及的GMP生产设施。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477169.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","CDMO","BK1515","BK1161","BK4139","BK4588","159938","KCAI","09939","06628","VXUS","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657766762","title":"创胜集团医药-B出售CDMO资产 交易总价1.9亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2657766762","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657766762?lang=zh_cn&edition=full","pubTime":"2026-08-07 08:50","pubTimestamp":1786063800,"startTime":"0","endTime":"0","summary":"8月7日，创胜集团医药-B（06628）发布公告，董事会于2026年8月6日宣布，公司全资附属公司杭州奕安济世生物药业有限公司与买方杭州明德生物医药技术有限公司签订了资产购买协议，出售CDMO资产，交易总价为1.9亿元。交易完成后，公司将不再持有CDMO资产的任何权益。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608073834582979.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608073834582979.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["06628","BK4139","09939","BK1515","159938","CDMO","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657669070","title":"创胜集团医药-B(06628.HK)拟1.9亿元出售CDMO资产","url":"https://stock-news.laohu8.com/highlight/detail?id=2657669070","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657669070?lang=zh_cn&edition=full","pubTime":"2026-08-07 06:36","pubTimestamp":1786055801,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655832649","title":"【券商聚焦】国泰海通证券：全球多肽CDMO进入产能扩张周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2655832649","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2655832649?lang=zh_cn&edition=full","pubTime":"2026-07-29 09:21","pubTimestamp":1785288070,"startTime":"0","endTime":"0","summary":"国内外的多肽CDMO公司均加大对于产能的投资建设，尤其注重从临床前到商业化生产的一站式服务能力建设。2026年4月，凯莱英医药与天津经开区管委会签署合作备忘录，在天津经开区持续扩建化学大分子创新药CDMO研发生产基地，预计投资规模达20亿元人民币。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MWIyNWQwZjQ4NTQyNjI4OTI5NDE=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986985","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0561508036.HKD","BK1583","LU0588546209.SGD","IE00B543WZ88.USD","02142","06160","09926","LU2476274308.USD","LU0052750758.USD","02611","LU0979878070.USD","LU2242644610.SGD","LU0307460666.USD","09688","SG9999002463.SGD","161027","01877","BK1588","601211","LU0417516738.SGD","IE00B5MMRT66.SGD","LU0348784397.USD","LU0181495838.USD","LU1328277881.USD","BK1564","BK1610","KURE","02616","02269","01177","HK0000165453.HKD","LU1720050803.USD","IE00B0JY6N72.USD","LU0359202008.SGD","LU1251922891.USD","BK1147","01801","LU0051755006.USD","LU0067412154.USD","LU1719994722.HKD","BK1141","LU1008478684.HKD","06185","BK1574","09995","CDMO","KCE","LU0634319403.HKD","01093"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772632","title":"中信建投：2026年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653772632?lang=zh_cn&edition=full","pubTime":"2026-07-24 08:20","pubTimestamp":1784852419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","BK4139","CXO","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646333550","title":"港股异动 | 创胜集团医药-B(06628)涨近4% 近期收到HiCB对外授权里程碑付款 CDMO业务取得稳步进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2646333550","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2646333550?lang=zh_cn&edition=full","pubTime":"2026-06-26 11:04","pubTimestamp":1782443087,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，创胜集团医药-B涨近4%，截至发稿，涨3.77%，报1.1港元，成交额13.63万港元。消息面上，近期，创胜集团医药-B发布公告，公司已收到来自其HiCB平台对外授权的一笔里程碑付款人民币700万元。迄今为止，创胜集团已成功完成关键可交付条件。同时，创胜集团的CDMO业务亦取得稳步进展。创胜集团目前亦就其他高潜力项目洽谈合约，包括综合IND开发项目、siRNA GMP药品生产、可开发性评估及为全球客户进行材料生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1459218.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06628","159938","09939","BK1515","BK4139","BK1574","VXUS","BK1161","BK4585","BK4588","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640520699","title":"新股消息 | 智享生物递表港交所 为中国第二大生物制剂CDMO公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2640520699","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640520699?lang=zh_cn&edition=full","pubTime":"2026-06-01 21:36","pubTimestamp":1780320982,"startTime":"0","endTime":"0","summary":"在中国，生物制剂CDMO市场规模由2020年的人民币91亿元扩大至2025年的人民币325亿元，期间年复合增长率为28.9%。中国生物制剂CDMO行业竞争激烈且高度集中。全球至少有150家生物制剂CDMO公司，其中至少25家位于中国。2025年，中国生物制剂CDMO市场总规模达人民币325亿元。2025年，在专注抗体药物的本土生物制剂CDMO中，公司在中国生物制剂CDMO市场中以收入计位列第三。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448756.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CDMO","IPOS","HEXmain","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638689303","title":"公告精选︱康龙化成：拟20亿元新建新药商业化生产和CDMO研发生产服务基地；华塑控股：未从事PCB生产业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2638689303","media":"格隆汇","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638689303?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:33","pubTimestamp":1779892385,"startTime":"0","endTime":"0","summary":"龙芯中科：拟定增募资不超23亿元","market":"sg","thumbnail":"https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/111.png?guru_height=540&guru_width=375"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4950239","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["BK1576","CDMO","PCB","BK0145","BK4139","BK0236","BK0095","000509","300759","03759","BK0102","BK4211","BK1141","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638659263","title":"创胜集团医药-B(06628)公布收到HiCB对外授权里程碑付款及CDMO业务稳步增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2638659263","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638659263?lang=zh_cn&edition=full","pubTime":"2026-05-26 16:35","pubTimestamp":1779784520,"startTime":"0","endTime":"0","summary":"智通财经APP讯，创胜集团医药-B 发布公告，公司已收到来自其HiCB平台对外授权的一笔里程碑付款人民币700万元，同时其CDMO业务亦取得重大进展。迄今为止，创胜集团已成功完成关键可交付条件。同时，创胜集团的CDMO业务亦取得稳步进展。随着HiCB对外授权项目取得进展以及CDMO业务持续扩张，创胜集团依然处于有利位置，以推动可持续增长并为其合作伙伴及股东创造长期价值。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1445970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06628","BK4139","09939","BK1515","159938","CDMO","BK1161","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635740188","title":"BioHarvest发布2026年业绩指引 D2C与CDMO双轮驱动","url":"https://stock-news.laohu8.com/highlight/detail?id=2635740188","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635740188?lang=zh_cn&edition=full","pubTime":"2026-05-15 03:06","pubTimestamp":1778785560,"startTime":"0","endTime":"0","summary":"　　植物细胞培养生物技术公司BioHarvest Sciences近日公布2026年第一季度财报。数据显示，公司一季度营收达850万美元，同比增长8%，略高于市场预期。现金及存款从去年同期的340万美元大幅增至2020万美元。　　公司首席执行官Zaki Rakib在财报电话会议上重申了2026年全年业绩指引。2026年5月，BioHarvest签署了价值120万美元的第二阶段合同，用于开发应用于全球香精行业的稀有产香植物。根据协议，BioHarvest将保留所开发组合物20%的所有权，并担任制造主体。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-15/doc-inhxwzrv6517436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4139","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633543917","title":"CDMO龙头三星生物罢工：中国CDMO企业迎订单转移窗口期？","url":"https://stock-news.laohu8.com/highlight/detail?id=2633543917","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2633543917?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:23","pubTimestamp":1778232180,"startTime":"0","endTime":"0","summary":"【CDMO龙头三星生物罢工：中国CDMO企业迎订单转移窗口期？】全球生物医药合同研发生产组织（CDMO）行业的“定海神针”正面临成立以来的最大运营危机。根据公开信息，2026年5月1日起，全球生物药CDMO产能排名第一的韩国三星生物爆发全面罢工，这也是该公司自2011年成立以来的首次全线停工。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605083731575828.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605083731575828.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","BK4585","BK4588","CDMO","EMXC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631686139","title":"康龙化成：小分子CDMO一季度订单加速增长来自两方面因素","url":"https://stock-news.laohu8.com/highlight/detail?id=2631686139","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2631686139?lang=zh_cn&edition=full","pubTime":"2026-04-30 16:30","pubTimestamp":1777537800,"startTime":"0","endTime":"0","summary":"证券日报网4月30日讯，康龙化成在接受调研者提问时表示，小分子CDMO一季度订单加速增长来自两方面因素，分别是项目数量增加、项目进入中后期后带来的订单金额提升，其中FollowMolecule项目从早期进入后期带来的订单额放大是核心的贡献因素。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202604303726489341.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202604303726489341.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["03759","BK4139","BK1576","300759","BK0216","BK1141","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630360531","title":"诚达药业2025年营收4.06亿元增21.99%，CDMO成第一大收入来源，扣非净利仍亏2669.29万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630360531","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630360531?lang=zh_cn&edition=full","pubTime":"2026-04-27 18:11","pubTimestamp":1777284689,"startTime":"0","endTime":"0","summary":"数据显示，公司2025年实现营业收入4.06亿元，同比增长21.99%；归母净利润为-1192.58万元，同比增加57.56%；扣非净利润为-2669.29万元，同比增加53.72%。CDMO产品收入占比升至40.60%，首次成为第一大收入来源；左旋肉碱系列产品收入占比为58.73%，退居第二。2025年第四季度单季营业收入为1.21亿元；归母净利润为-2869.91万元；扣非净利润为-3059.55万元，当季扣非净利润亏损额高于全年累计值，表明全年经营性减亏成果未能延续至年末，Q4盈利压力明显加大。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1777283201647343535","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["301201","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630364329","title":"高盛：内地CDMO板块稳健 看好药明康德(02359)、凯莱英(06821)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2630364329","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630364329?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:25","pubTimestamp":1777281907,"startTime":"0","endTime":"0","summary":"股份方面，该行对评级为“买入”的股份持更正面态度，包括药明康德 、凯莱英 、微创机器人 及精锋医疗 。另外，该行将爱康医疗 评级升至“买入”，反映其执行力重启、利润率改善及中期能见度更清晰，并将微泰医疗 升级至“中性”，因国内竞争影响优于预期，且有序达成2026年指引。前者受累于持续的VBP相关利润压力及短期增长乏力，后者收入加速回升但仍不明朗，上行空间有限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434465.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1969619763.USD","LU1328615791.USD","BK0132","LU2328871848.SGD","BK0239","BK1141","LU0348766576.USD","LU1808992512.USD","LU1997244956.HKD","LU2242644610.SGD","002821","LU1997245094.SGD","06821","LU1979443071.USD","BK1222","LU1997245177.USD","LU2495084118.USD","CDMO","02359","BK4139","LU1934453819.USD","02252","LU0320764599.SGD","BK1191","LU0287142896.SGD","LU0348767384.USD","LU0456842615.SGD","LU2045819591.USD","LU2125910500.SGD","BK1585","LU2488822045.USD","LU0052750758.USD","BK1617","01789","LU0173614495.USD","02675","603259","LU0708995583.HKD","BK1100","BK1583","BK1576","BK0216","LU1046422090.SGD","01066","BK1589"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630325361","title":"褪去新冠商业化红利反而更强了！药明康德(02359)小分子CDMO单季度收入飙至69.3亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630325361","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2630325361?lang=zh_cn&edition=full","pubTime":"2026-04-27 17:17","pubTimestamp":1777281471,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月27日晚间，药明康德发布了其首季度财报，核心业务增长动能强劲。此次小分子CDMO业务单季收入逼近70亿元大关，具有非凡的里程碑意义。数据显示，截至一季度末，药明康德小分子CDMO管线总数已达3550个。此次小分子CDMO业务在“后新冠时代”创下收入新高，是药明康德从“事件驱动”增长全面转向“平台驱动”持续高增长的有力证明，也为其在全球医药产业链中的核心枢纽地位再添坚实注脚。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1434451.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2328871848.SGD","BK0216","LU0052750758.USD","LU1997244956.HKD","BK1576","LU0348766576.USD","BK1141","CDMO","LU0456842615.SGD","02359","BK4139","LU1046422090.SGD","LU2488822045.USD","LU2242644610.SGD","BK1583","LU1969619763.USD","LU2495084118.USD","LU1979443071.USD","LU2125910500.SGD","LU0708995583.HKD","LU0320764599.SGD","LU2045819591.USD","603259","LU1808992512.USD","LU1934453819.USD","LU1997245094.SGD","LU0348767384.USD","LU1997245177.USD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.avidbio.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0027},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1499},{"period":"1year","weight":0.2011},{"period":"ytd","weight":0.1338}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Avid Bioservices, Inc.最初于1981年6月在美国加州注册成立，并于1996年9月25日在美国特拉华州重新合并。该公司是一家专门的合同开发和制造组织（“CDMO”），提供从工艺开发到当前良好制造实践的全方位服务（“CGMP”）临床和商业制造，专注于从哺乳动物细胞培养中提取生物制药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.645161,"avgChangeRate":0.245054},{"month":2,"riseRate":0.580645,"avgChangeRate":0.056406},{"month":3,"riseRate":0.466667,"avgChangeRate":-0.035156},{"month":4,"riseRate":0.4,"avgChangeRate":-0.032334},{"month":5,"riseRate":0.516129,"avgChangeRate":0.109027},{"month":6,"riseRate":0.419355,"avgChangeRate":0.007765},{"month":7,"riseRate":0.322581,"avgChangeRate":0.039463},{"month":8,"riseRate":0.354839,"avgChangeRate":0.002481},{"month":9,"riseRate":0.387097,"avgChangeRate":-0.046446},{"month":10,"riseRate":0.354839,"avgChangeRate":-0.040707},{"month":11,"riseRate":0.548387,"avgChangeRate":0.073378},{"month":12,"riseRate":0.419355,"avgChangeRate":0.023819}],"exchange":"NASDAQ","name":"Avid Bioservices, Inc.","nameEN":"Avid Bioservices, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Avid Bioservices, Inc.,CDMO,Avid Bioservices, Inc.股票,Avid Bioservices, Inc.股票老虎,Avid Bioservices, Inc.股票老虎国际,Avid Bioservices, Inc.行情,Avid Bioservices, Inc.股票行情,Avid Bioservices, Inc.股价,Avid Bioservices, Inc.股市,Avid Bioservices, Inc.股票价格,Avid Bioservices, Inc.股票交易,Avid Bioservices, Inc.股票购买,Avid Bioservices, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Avid Bioservices, Inc.(CDMO)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Avid Bioservices, Inc.(CDMO)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}